Intuitive beats quarterly profit estimates on strong demand for surgical robots
Oct 17 (Reuters) -Medical device maker Intuitive Surgical ISRG.O beat Wall Street estimates for third-quarter profit on Thursday, helped by strong demand for its surgical robots used in minimally invasive procedures, sending shares up 6% in extended trading.
The company earned $1.84 per share on an adjusted basis for the quarter ended Sept. 30, beating analysts' average estimate of $1.63, according to data compiled by LSEG.
Medical device manufacturers have been benefiting from elevated demand for non-urgent surgeries as people, especially older Americans, catch up on procedures deferred during the pandemic.
Intuitive's surgical robots, da Vinci, are widely used for a range of procedures, including weight-loss surgeries and for conditions of the digestive system, bladder and heart.
Third-quarter volume of da Vinci procedures rose about 18% from a year ago, the company said.
Industry bellwether Johnson & Johnson's JNJ.N medical technology business sales rose nearly 6% to $7.9 billion in the third quarter, but fell short of estimates due to headwinds in the Asia-Pacific region, including China and Japan.
Meanwhile, larger peer Abbott Laboratories ABT.N slightly lifted its annual profit forecast on Wednesday, driven by strong demand for its medical devices, especially those that are used in diabetes care.
Sunnyvale, California-based Intuitive Surgical posted a revenue of $2.04 billion for the third quarter, in line with analyst estimates.
Sales at its instruments and accessories unit, which accounts for a major chunk of the revenue, rose 18% to $1.26 billion from a year ago, compared with estimates of $1.25 billion.
Reporting by Mariam Sunny in Bengaluru; Editing by Shreya Biswas
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
